The Byzantine system for degrading proteins inside cells is already the target of a successful anticancer drug. A compound that inhibits another part of this system also shows promise in models of cancer in mice.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
The Biopharmaceutical Sector's Impact on the U.S. Economy: Analysis at the National, State, and Local Levelshttp://www.archstoneconsulting.com/biopharmapdf/report.pdf (2009).
Soucy, T. A. et al. Nature 459, 732–736 (2009). | Article |
Pickart, C. M. Cell 116, 181–190 (2004).
Kane, R. C., Bross, P. F., Farrell, A. T. & Pazdur, R. Oncologist 8, 508–513 (2003).
Rock, K. L. et al. Cell 78, 761–771 (1994).
Adams, J. et al. Bioorg. Med. Chem. Lett. 8, 333–338 (1998).
Petroski, M. D. & Deshaies, R. J. Nature Rev. Mol. Cell Biol. 6, 9–20 (2005).
Lammer, D. et al. Genes Dev. 12, 914–926 (1998).
Liakopoulos, D., Doenges, G., Matuschewski, K. & Jentsch, S. EMBO J. 17, 2208–2214 (1998).
Walden, H., Podgorski, M. S. & Schulman, B. A. Nature 422, 330–334 (2003).
Saha, A. & Deshaies, R. J. Mol. Cell 32, 21–31 (2008).
Duda, D. M. et al. Cell 134, 995–1006 (2008).
Leyser, H. M. et al. Nature 364, 161–164 (1993).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Deshaies, R. Fresh target for cancer therapy. Nature 458, 709–710 (2009). https://doi.org/10.1038/458709a
Published:
Issue Date:
DOI: https://doi.org/10.1038/458709a
